|
2025
|
Invention
|
Fluticasone furoate in the treatment of copd.
The present invention relates to pharmaceutical pr... |
|
|
Invention
|
Combination treatment for cancer.
Disclosed herein is a method of treating cancer, such as multi... |
|
2024
|
Invention
|
Anti-bcma antibody drug conjugate combination treatment for cancer.
Disclosed herein is a method... |
|
|
Invention
|
Baff specific antibodies. The present invention relates to anti-BLyS antigen binding proteins suc... |
|
|
Invention
|
Il-33 binding antibodies. The present disclosure relates to the treatment of interleukin 33 (IL-3... |
|
|
Invention
|
5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bh)-one compounds and methods... |
|
|
Invention
|
Compositions and methods for producing smooth muscle cells. Methods and compositions are provided... |
|
|
Invention
|
Compositions and methods for producing smooth muscle cells.
Methods and compositions are provide... |
|
|
Invention
|
Compositions and methods for producing primordial germ cell-like cells. Methods and compositions ... |
|
|
Invention
|
Compositions and methods for producing primordial germ cell-like cells.
Methods and compositions... |
|
|
Invention
|
Androgen receptor protacs. The present invention provides Androgen receptor PROTACs containing a ... |
|
|
Invention
|
Methods of producing nucleotide triphosphates (ntps). The invention relates to a novel enzymatic ... |
|
|
Invention
|
Il-7 binding proteins and their use in medical therapy.
Provided herein are interleukin 7 (IL-7)... |
|
|
Invention
|
Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells.
The present ... |
|
|
Invention
|
Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells.
The pre... |
|
|
Invention
|
Cytotoxicity targeting chimeras for folate receptor-expressing cells.
The present disclosure rel... |
|
|
Invention
|
Cytotoxicity targeting chimeras for ccr2-expressing cells.
The present disclosure relates to het... |
|
|
Invention
|
Cytotoxicity targeting chimeras for cxcr3-expressing cells.
The present disclosure relates to he... |
|
|
Invention
|
Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells.
The present discl... |
|
|
Invention
|
Heterocyclic compounds and their use in the treatment of mycobacterial infections. The invention ... |
|
|
Invention
|
Pi4kiiibeta inhibitors.
The invention relates to compounds of formula (I) which are inhibitors o... |
|
|
Invention
|
Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an ... |
|
|
Invention
|
Compounds.
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, proce... |
|
|
Invention
|
Cytotoxicity targeting chimeras for car-t and car-nk cells. The present disclosure relates to het... |
|
|
Invention
|
Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies. The prese... |
|
|
Invention
|
Bispecific cytotoxicity targeting chimeras. The present disclosure relates to heterotrifunctional... |
|
|
Invention
|
Methods of treating chronic hepatitis b. The present disclosure relates to methods for treating a... |
|
|
Invention
|
Biopharmaceutical compositions and related methods.
The present disclosure relates to compositio... |
|
|
Invention
|
System. The present invention relates to novel systems, polypeptides, compounds and methods. The ... |
|
|
Invention
|
Hydroxypyridoxazepines as nrf2 activators.
The present invention relates hydroxypyridoxazepine c... |
|
|
Invention
|
Methods of treating atopic dermatitis. The disclosure provides a method of treating atopic dermat... |
|
2023
|
Invention
|
Method of treating pain with an anti-ccl17 antibody. A method for treating chronic pain in a huma... |
|
|
Invention
|
Methods of treatment using b-cell maturation antigen antagonists. The disclosure provides methods... |
|
|
Invention
|
Substituted pyridines as dnmt1 inhibitors. The invention relates to substituted pyridine derivati... |
|
|
Invention
|
2,4-dioxotetrahydropyrimidinyl deratives as degrons in protacs.
The present invention provides a... |
|
|
Invention
|
Compounds.
The invention relates to compounds or pharmaceutically acceptable salts thereof, comp... |
|
|
Invention
|
Mitigating ocular toxicity.
Aspects of the disclosure are directed to mitigating ocular toxicity... |
|
|
Invention
|
High-throughput assay for cell migration, chemotaxis, and function.
An assay system permits stud... |
|
|
Invention
|
Combination therapy for treating hepatitis b virus infections.
The present disclosure is related... |
|
|
Invention
|
Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus sapr... |
|
2022
|
Invention
|
Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic ... |
|
|
Invention
|
Pyrazine compounds useful in the treatment of parasitic protozoal infection.
The present applica... |
|
|
Invention
|
Display screen with graphical user interface |
|
|
Invention
|
Cytotoxicity targeting chimeras.
The present disclosure relates to heterobifunctional molecules,... |
|
|
Invention
|
Biopharmaceutical compositions and stable isotope labeling peptide mapping method.
Disclosed her... |
|
|
Invention
|
Pharmaceutical compound.
The present application relates to compounds of Formula (I) or a pharma... |
|
|
Invention
|
Oral solid dose formulations.
Disclosed are novel pharmaceutical compositions comprising gepotid... |
|
2021
|
Invention
|
Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8... |
|
2018
|
Invention
|
Novel processes for the production of oligonucleotides.
The invention relates to novel processes... |
|
2002
|
G/S
|
Pharmaceutical, veterinary and sanitary products; dietetic
substances for medical use, food for ... |
|
2000
|
G/S
|
Pharmaceutical products and specialties acting on the
central nervous system. |
